Witten, Germany

Hautarztpraxis Dr. med. Matthias Hoffmann

Dermatitis

Psoriasis

Eczema

Atopic Dermatitis

Skin Diseases

Prurigo

Upadacitinib

HRO350

Ruxolitinib

AbbVie

Arctic Bioscience

Incyte

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

Hautarztpraxis Dr. med. Matthias Hoffmann | Witten, Germany

Site insights

Work at this site?

Active trials

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

Trial sponsors